Eli Lilly and Company (NYSE:LLY) Stake Boosted by Hazlett Burt & Watson Inc.

Hazlett Burt & Watson Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,458 shares of the company’s stock after buying an additional 109 shares during the quarter. Hazlett Burt & Watson Inc.’s holdings in Eli Lilly and Company were worth $1,293,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of Eli Lilly and Company by 19.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares during the period. Quent Capital LLC boosted its position in Eli Lilly and Company by 5.3% in the 1st quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock valued at $3,846,000 after buying an additional 249 shares during the last quarter. Mutual Advisors LLC increased its position in Eli Lilly and Company by 404.8% in the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock worth $48,699,000 after purchasing an additional 50,197 shares during the period. Whittier Trust Co. grew its position in shares of Eli Lilly and Company by 52.2% during the 1st quarter. Whittier Trust Co. now owns 75,487 shares of the company’s stock worth $58,725,000 after buying an additional 25,877 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. raised its position in shares of Eli Lilly and Company by 155.1% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 19,745 shares of the company’s stock valued at $15,361,000 after acquiring an additional 12,004 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 1.6 %

Shares of Eli Lilly and Company stock opened at $806.14 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $765.28 billion, a price-to-earnings ratio of 87.15, a PEG ratio of 3.09 and a beta of 0.43. The firm’s 50-day moving average price is $908.15 and its two-hundred day moving average price is $867.39. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue was up 20.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. On average, analysts forecast that Eli Lilly and Company will post 13.23 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on LLY. Citigroup lifted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. BMO Capital Markets boosted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.